Actively Recruiting
CD19/22 Bi-specific CAR-T Cell Therapy
Led by Shenzhen Geno-Immune Medical Institute · Updated on 2022-06-27
60
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the feasibility, safety and efficacy of anti-CD19/22 bi-specific CAR-T cell therapy in patients with CD19 and/or CD22 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/22 bi-specific CAR-T cells and their persistency in patients.
CONDITIONS
Official Title
CD19/22 Bi-specific CAR-T Cell Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age older than 6 months
- Malignant B cell surface expression of CD19 or CD22 molecules
- Karnofsky Performance Status (KPS) score over 80 points
- Expected survival time of more than 1 month
- Hemoglobin greater than 80 g/L
- No contraindications to blood cell collection
You will not qualify if you...
- Presence of other active diseases that make patient response difficult to assess
- Uncontrolled bacterial, fungal, or viral infections
- Living with HIV
- Active hepatitis B or hepatitis C infection
- Pregnant or nursing mothers
- Systemic steroid treatment within a week before treatment
- Prior failed treatment with CD19 and CD22 CAR-T therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China, 518000
Actively Recruiting
Research Team
L
Lung-Ji Chang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here